Eldorado Gold SEC Filings

Eldorado Gold Corporation (EGO) filed Amendment No. 1 to its Form F-10 registration statement. The only substantive change is an increase of $6,532 in the registered amount to allow inclusion of the required iXBRL filing-fee-table exhibit that was mistakenly omitted in the original June 17, 2025 submission. No other disclosure—including financial statements, business description, risk factors, or use of proceeds—has been updated or restated. The amendment reiterates standard CBCA indemnification language for directors and officers, lists previously filed exhibits, and provides routine consents, signatures, and undertaking/agent information. As such, the filing is primarily administrative and does not alter Eldorado Gold’s capital-raising plans, operating outlook, or financial condition.

Bank of Montreal (Series K) Autocallable Barrier Notes with Memory Coupons linked to Amazon.com, Inc. (AMZN) were priced on 26 June 2025 and settle on 30 June 2025. The US$4.88 million issuance is offered in $1,000 denominations and is not listed on any exchange. All payments are subject to BMO’s credit risk.

Coupon mechanics

• Contingent Interest Rate: 2.50% per quarter (≈10.00% p.a.).
• Coupon Barrier: 70% of the Initial Level (AMZN $151.98).
• Memory feature: any missed coupons are banked and paid the next time AMZN closes ≥ Coupon Barrier.
• If AMZN closes < Coupon Barrier on every Observation Date, investors receive no coupons.

Autocall feature

• Starting 26 December 2025, the notes are automatically redeemed if AMZN closes > 100% of the Initial Level ($217.12) on any quarterly Observation Date.
• Investors then receive par plus any due contingent coupons; no further cash-flows accrue.

Maturity payoff (30 June 2028)

• If not previously called and no Trigger Event (AMZN final level ≥ 70% of Initial Level), investors receive par plus any due coupons.
• If a Trigger Event occurs (final level < 70% of Initial Level), principal is reduced 1 % for every 1 % decline in AMZN from the Initial Level—down to zero in a worst-case scenario.

Key terms

• Initial Level: AMZN $217.12.
• Trigger/Barrier: $151.98 (70% of Initial Level).
• Estimated initial value: $970.53 per $1,000 note (3.0 % discount to par reflects fees/hedging costs).
• Agent’s commission: 2.50% ($122,000); net proceeds 97.50%.

Principal risks highlighted by the issuer

• Principal loss: investors bear downside below 70% barrier.
• Conditional coupons: payments cease whenever the stock trades below the barrier; none are guaranteed.
• Limited upside: return capped at coupon income; no participation in AMZN appreciation.
• Liquidity: no exchange listing; secondary market, if any, only through BMOCM.
• BMO credit risk: unsecured senior debt of Bank of Montreal.
• Tax uncertainty: treated as pre-paid contingent income-bearing derivative; IRS treatment could differ.

These notes appeal to investors comfortable with single-stock volatility who seek double-digit conditional income and a 30 % downside buffer, but they must accept potential 100 % principal loss, call risk, illiquidity, and credit exposure to BMO.

Medicus Pharma Ltd. (Nasdaq: MDCX) has filed Prospectus Supplement No. 5 to update its May 29, 2025 prospectus in connection with a definitive securities-exchange agreement signed on June 29, 2025. The company will acquire 100% of Antev Ltd., a clinical-stage biotech developing Teverelix, a next-generation GnRH antagonist targeting cardiovascular high-risk prostate-cancer patients and acute urinary-retention episodes.

Key agreed terms:

• Equity consideration: 2,666,600 Medicus common shares, equal to roughly 17 % of post-transaction shares outstanding ("Consideration Shares").
• Lock-up & voting: Consideration Shares subject to staggered resale restrictions and a 36-month voting agreement in favor of current Medicus management.
• Earn-outs: Antev holders may receive up to US$65 million in contingent payments tied to FDA Phase 2 and NDA milestones for Teverelix.
• Closing timetable: Expected before the end of August 2025, pending Antev shareholder approval and customary regulatory/third-party consents. No assurance of completion is given.

The supplement also reminds investors that Medicus’ 2.26 million common shares are reserved for warrant exercises (strike $4.64, exp. Nov 15 2029). As of June 27 2025, Medicus shares traded at $2.90 and the public warrants at $0.95.

The company reiterates its emerging-growth-company status and directs investors to existing risk-factor disclosures. Forward-looking statements highlight uncertainties around deal consummation, clinical development, regulatory approval, and market opportunity for Teverelix.

Eldorado Gold Corporation (NYSE: EGO; TSX: ELD) submitted a Form 6-K dated 23 June 2025. The filing is limited to administrative matters: it notifies the SEC that the company has adopted an Amended and Restated Stock Option Plan (Exhibit 99.1) and an Amended and Restated Performance Share Unit (PSU) Plan (Exhibit 99.2). No operating, financial or transaction-related information is provided. The document is signed by Corporate Secretary Karen Aram and indicates Eldorado continues to file its periodic reports under Form 40-F, consistent with its status as a Canadian foreign private issuer.

Because the submission only updates equity-based compensation frameworks and contains no quantitative data on earnings, cash flow, reserves or capital projects, the immediate market impact is expected to be limited. However, the revised incentive plans may influence future dilution levels, executive alignment and governance metrics once the full plan details are reviewed.

Eldorado Gold (NYSE:EGO) filed a Form SD for the fiscal year ended December 31, 2024 under Rule 13q-1, which requires resource-extraction issuers to disclose payments made to governments.

The company is using the alternative reporting provision and has submitted its Canadian Extractive Sector Transparency Measures Act (ESTMA) report as Exhibit 2.01. The filing confirms that conflict-minerals disclosure is not applicable for this period and contains no financial statements, operational updates, risk factors or legal proceedings. Investors can access the full ESTMA report through Eldorado’s website or the Government of Canada portal.